Papers
4
Total Citations
42
H-Index
4
About
Paul Zuck is a pioneering figure in the development of automated platforms for drug discovery and infectious disease research. His work centers on creating high-throughput, miniaturized assays that accelerate the identification of novel therapeutics. Zuck’s major contributions include the development of fluorogenic substrates for measuring endothelial lipase activity, a critical tool for discovering inhibitors that regulate HDL cholesterol levels. He has also advanced the fight against HIV by establishing an automated platform for modeling latency reversal with HDAC inhibitors, enabling more efficient screening of potential cure strategies. In antibacterial research, Zuck created a fully automated system for agar-based measurement of viable bacterial growth, significantly streamlining pharmacodynamic studies. His 2016 work on a platform for fully automated cross-titration experiments further exemplifies his commitment to removing bottlenecks in lead optimization. While his most-cited paper (24 citations) focuses on endothelial lipase, his broader impact lies in the design and implementation of automated, high-throughput systems that transform complex biological questions into scalable, reproducible experiments. Zuck’s innovations are essential for researchers seeking to bridge the gap between in vitro discovery and in vivo translation.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4